Wealth Enhancement Advisory Services LLC Sells 45,301 Shares of Zoetis Inc. $ZTS

Wealth Enhancement Advisory Services LLC lessened its stake in Zoetis Inc. (NYSE:ZTS) by 29.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 107,168 shares of the company’s stock after selling 45,301 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Zoetis were worth $15,300,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Halbert Hargrove Global Advisors LLC increased its position in shares of Zoetis by 496.6% during the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after acquiring an additional 144 shares during the period. REAP Financial Group LLC grew its stake in Zoetis by 201.5% in the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock worth $31,000 after purchasing an additional 131 shares in the last quarter. NewSquare Capital LLC grew its stake in Zoetis by 69.1% in the second quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock worth $32,000 after purchasing an additional 85 shares in the last quarter. ORG Partners LLC increased its holdings in Zoetis by 56.8% during the 2nd quarter. ORG Partners LLC now owns 232 shares of the company’s stock worth $37,000 after purchasing an additional 84 shares during the period. Finally, Financial Consulate Inc. bought a new stake in Zoetis during the 3rd quarter valued at $39,000. Institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

ZTS opened at $124.35 on Friday. The firm has a market capitalization of $54.80 billion, a PE ratio of 20.93, a price-to-earnings-growth ratio of 2.17 and a beta of 0.97. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.64 and a quick ratio of 2.28. The business’s 50-day moving average is $123.51 and its two-hundred day moving average is $138.66. Zoetis Inc. has a 1 year low of $115.25 and a 1 year high of $177.40.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The business had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.42 billion. During the same period last year, the business earned $1.58 EPS. The company’s revenue was up .5% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Research analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 3rd. Shareholders of record on Tuesday, January 20th will be issued a $0.53 dividend. This is an increase from Zoetis’s previous quarterly dividend of $0.50. This represents a $2.12 annualized dividend and a yield of 1.7%. The ex-dividend date of this dividend is Tuesday, January 20th. Zoetis’s dividend payout ratio is presently 35.69%.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on ZTS shares. Barclays started coverage on Zoetis in a research report on Monday, December 8th. They set an “equal weight” rating and a $136.00 price target on the stock. KeyCorp started coverage on shares of Zoetis in a research note on Thursday, November 20th. They issued a “sector weight” rating for the company. HSBC set a $140.00 target price on shares of Zoetis in a report on Wednesday, December 10th. Weiss Ratings upgraded shares of Zoetis from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, January 13th. Finally, Bank of America cut shares of Zoetis from a “buy” rating to a “neutral” rating and set a $135.00 price target for the company. in a research report on Monday, December 15th. Five investment analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $152.91.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.